Clinical trials: Acarbose
Type 2 Diabetes Mellitus
24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
SMART Study - A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared with Acarbose when in Combination with…
- Trial name
- SMART (NCT02243176)
- Testing
- Saxagliptin, Acarbose
- Where
- China
- Volunteers
- 689 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients
Primary objective To evaluate the efficacy of Acarbose add-on therapy on glucose control in subjects with type 2 diabetes inadequately controlled with Metformin and Sitagliptin combination therapy.
- Trial name
- NCT01490918
- Testing
- Acarbose
- Where
- South Korea
- Volunteers
- 165 people
- Sponsor
- The Catholic University of Korea
Aging
Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C)
This study addresses a "lifespan approach to healthy development and aging" with direct relevance to humans by testing the anti-aging effects of acarbose in humans.
- Trial name
- NCT02865499
- Testing
- acarbose
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus
A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
To assess the effect of adding acarbose or repaglinide or gliclazide to sitagliptin plus metformin, compared to adding glimepiride, on glycemic improvements in Type 2 Diabetes Mellitus (T2DM) participants who require the addition…
- Trial name
- NCT01709305
- Testing
- Metformin, Sitagliptin, Acarbose
- Volunteers
- 5,570 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes
The primary purpose of this study is to evaluate the efficacy of voglibose versus acarbose combined with metformin in participants with type 2 diabetes mellitus (T2DM) by evaluating levels of glycosylated hemoglobin.
- Trial name
- NCT02049814
- Testing
- Metformin, Voglibose, Acarbose
- Where
- 18 sites in China
- Volunteers
- 494 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion
A 3-week, multi-center, open-label, randomized, active-control, parallel-group study to compare effects of Nateglinide and Acarbose on postprandial glucose fluctuation in Chinese drug-naive patients type 2 diabetes mellitus…
- Trial name
- NCT01030952
- Testing
- Nateglinide, Acarbose
- Where
- 3 sites in China
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Pediatric Obesity, Insulin Resistance
Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity
The main purpose of this study is to determine whether treatment with acarbose attenuates post-prandial glycemic excursions in non-diabetic/pre-diabetic obese children as determined by continuous glucose monitoring systems…
- Conditions
- Pediatric Obesity, Insulin Resistance, Impaired Glucose Tolerance, Cardiovascular Disease
- Trial name
- NCT00846521
- Testing
- Acarbose
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Yale University
Type 2 Diabetes Mellitus
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
This study will evaluate whether the addition of sitagliptin reduces hemoglobin A1C (A1C) more than the addition of placebo for participants with type 2 diabetes mellitus (T2DM) on a steady dose of acarbose.
- Trial name
- NCT01177384
- Testing
- Sitagliptin phosphate, Acarbose, Glimepiride
- Volunteers
- 380 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)
The purpose of this pilot trial is to determine whether an intensive treatment with insulin glargine, metformin, acarbose and lifestyle can normalize blood glucose levels in patients with recently diagnosed type 2 diabetes…
- Trial name
- NCT01181674
- Testing
- insulin glargine, metformin, acarbose
- Where
- Canada
- Volunteers
- 83 people
- Sponsor
- Population Health Research Institute
Aging
Study of Acarbose in Longevity
The investigators are studying the effects of acarbose on muscle and adipose gene transcription in older adults.
- Trial name
- SAIL (NCT02953093)
- Testing
- Acarbose
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Diabetes Mellitus, Type 2
Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors
This study was conducted to demonstrate superiority of nateglinide in postprandial glucose fluctuation, dyslipidemia, and inflammatory status improvement.
- Trial name
- ENERGY (NCT00928889)
- Testing
- Nateglinide 120 mg, Acarbose 50 mg
- Where
- 6 sites in China
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals